Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma
| Autor: | Hart S. Dengler, Naomi S. Rajapaksa, Mark Zak |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Side effect
Drug Compounding medicine.medical_treatment Clinical Biochemistry Pharmaceutical Science Disease 01 natural sciences Biochemistry Autoimmune Diseases Therapeutic index Administration Inhalation Drug Discovery medicine Animals Humans Janus Kinase Inhibitors Phosphorylation Lung Molecular Biology Janus Kinases Asthma Molecular Structure 010405 organic chemistry Chemistry Organic Chemistry medicine.disease 0104 chemical sciences Drug Liberation 010404 medicinal & biomolecular chemistry Treatment Outcome medicine.anatomical_structure Cytokine Rheumatoid arthritis Immunology Cytokines Molecular Medicine Janus kinase Signal Transduction |
| Zdroj: | Bioorganic & Medicinal Chemistry Letters. 29:126658 |
| ISSN: | 0960-894X |
| DOI: | 10.1016/j.bmcl.2019.126658 |
| Popis: | Multiple asthma-relevant cytokines including IL-4, IL-5, IL-13, and TSLP depend upon JAKs for signaling. JAK inhibition may, therefore, offer a novel intervention strategy for patients with disease refractory to current standards of care. Multiple systemically delivered JAK inhibitors have been approved for human use or are under clinical evaluation in autoimmune diseases such as rheumatoid arthritis. However, the on-target side effect profiles of these agents are likely not tolerable for many asthmatic patients. Limiting JAK inhibition to the lung is expected to improve therapeutic index relative to systemic inhibition. Thus, inhaled JAK inhibitors with lung-restricted exposure are of high interest as potential treatments for asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect